ReviewFrontiers in immunology2022
B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Multiplex immunofluorescence in the identification of immune cell compositions in rejection, bronchus-associated lymphoid tissue, and infection in lung allograft tissue.Virchows Archiv : an international journal of pathology · 2026Article
- Regulatory T cells in cardiac allograft vasculopathy: from mechanistic insights to clinical tolerance.Frontiers in immunology · 2026Review
- B cell-mediated immune reconstitution after lung transplantation: mechanisms, interventions, and prognostic evaluation.Frontiers in immunology · 2026Review
- Population-agnostic real-time molecular mismatch estimation using rSSO-defined HLA allele strings: minimal impact of allelic discordance with NGS.Frontiers in immunology · 2026Article
- M2 macrophage polarization in allogeneic skin transplantation: from intrinsic mechanisms to clinical prospects for immune tolerance.Molecular biology reports · 2025Review
- Review
- Chronic rejection models for vascularized composite tissue allotransplantation.Scientific reports · 2025Article
- Pharmacodynamics monitoring after lung transplantation.JHLT open · 2025Review
- High-dimensional flow cytometry reveals lymphocyte subset populations predictive of chronic lung allograft dysfunction.Clinical & translational immunology · 2025Article
- Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2024Review
- Dynamic establishment and maintenance of the human intestinal B cell population and repertoire following transplantation in a pediatric-dominated cohort.Frontiers in immunology · 2024Article
- Anti-CD20 Antibody and Calcineurin Inhibitor Combination Therapy Effectively Suppresses Antibody-Mediated Rejection in Murine Orthotopic Lung Transplantation.Life (Basel, Switzerland) · 2023Article
- Mesenchymal Stromal Cell Therapy in Lung Transplantation.Bioengineering (Basel, Switzerland) · 2023Review
- Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol.Medicina (Kaunas, Lithuania) · 2023Article
- Recent advances and limitations of mTOR inhibitors in the treatment of cancer.Cancer cell international · 2022Review
- Balancing B cell responses to the allograft: implications for vaccination.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly recognized as modulators of alloimmunity and initiators of a donor-specific humoral response. In chronically rejected lung allografts, B cells contribute to the formation of tertiary lymphoid structures and promote local alloimmune responses. However, B cells are functionally heterogeneous and some B cell subsets may promote alloimmune tolerance. In this review, we describe the current understanding of B-cell-dependent mechanisms in pulmonary allograft rejection and highlight promising future strategies that employ B cell-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.